Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2023 financial results on Thursday, August 10, 2023. The Company will hold a conference call...
John Welborn, Jr. is appointed Chair of the Board, succeeding Greg Gubitz, who is retiring John Hanna is appointed to the HLS Board as an independent director TORONTO, June 22, 2023 /CNW/ - HLS...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...
HLS Directors J. Spencer Lanthier and Don DeGolyer will not be standing for re-election at the 2023 AGM Director Greg Gubitz to retire following 2023 AGM and Polar nominee to be appointed to the Board
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the...